Sierra Oncology Reports 2018 Year End Results

Thursday, February 28, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

SIERRA ONCOLOGY, INC. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data)

Three Months EndedDecember 31,

Year EndedDecember 31,

2018

2017

2018

2017

Operating expenses:

Research and development

$

11,046

$

7,550

$

41,078

$

30,157

General and administrative

3,603

3,255

14,339

12,462

Total operating expenses

14,649

10,805

55,417

42,619

Loss from operations

(14,649)

(10,805)

(55,417)

(42,619)

Other income, net

447

254

1,780

760

Loss before provision for (benefit from) income taxes, net

(14,202)

(10,551)

(53,637)

(41,859)

Provision for (benefit from) income taxes, net

81

48

(302)

156

Net loss

$

(14,283)

$

(10,599)

$

(53,335)

$

(42,015)

Net loss per common share, basic and diluted

$

(0.19)

$

(0.20)

$

(0.75)

$

(0.84)

Weighted-average shares used in computing net loss

 per common share, basic and diluted

74,365,632

52,330,334

70,739,210

49,899,299



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store